Hangzhou Biotest Biotech Co Ltd (688767) — Financial Flexibility Index
Hangzhou Biotest Biotech Co Ltd (688767) has a Financial Flexibility Index of 0.56x as of September 2025. Free cash flow of CN¥75.41 Million (operating CF CN¥28.39 Million minus capex CN¥47.02 Million) represents 1% of total liabilities (CN¥134.75 Million). Check 688767 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Hangzhou Biotest Biotech Co Ltd Financial Flexibility Index (2017–2025)
Historical Financial Flexibility Index trend for Hangzhou Biotest Biotech Co Ltd across 9 annual periods. For the full cash flow conversion analysis, see Hangzhou Biotest Biotech Co Ltd cash flow conversion.
Annual Financial Flexibility Index for Hangzhou Biotest Biotech Co Ltd (2017–2025)
Year-by-year free cash flow to debt coverage for Hangzhou Biotest Biotech Co Ltd. Explore Hangzhou Biotest Biotech Co Ltd debt service capacity to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 1.41x | CN¥236.34 Million | CN¥106.47 Million | CN¥168.17 Million | ▼ -28.7% |
| 2024 | 1.97x | CN¥373.88 Million | CN¥128.83 Million | CN¥189.79 Million | ▲ +66.6% |
| 2023 | 1.18x | CN¥187.80 Million | CN¥131.38 Million | CN¥158.82 Million | ▼ -74.7% |
| 2022 | 4.67x | CN¥882.13 Million | CN¥703.21 Million | CN¥188.92 Million | ▲ +36.2% |
| 2021 | 3.43x | CN¥1.11 Billion | CN¥908.12 Million | CN¥323.36 Million | ▲ +29.9% |
| 2020 | 2.64x | CN¥503.75 Million | CN¥446.07 Million | CN¥190.89 Million | ▲ +242.3% |
| 2019 | 0.77x | CN¥65.14 Million | CN¥25.67 Million | CN¥84.50 Million | ▲ +28.7% |
| 2018 | 0.60x | CN¥33.84 Million | CN¥21.17 Million | CN¥56.48 Million | ▼ -14.2% |
| 2017 | 0.70x | CN¥33.44 Million | CN¥7.07 Million | CN¥47.88 Million | — |